Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer

NCT00170157 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00170157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00170157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
June 30, 2013
Enrollment
112 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer